Author name: Peplife Research

Cagrilintide and eloralintide act through the amylin receptor, tirzepatide and retatrutide through the incretin receptors. Two tables setting the published outcomes and tolerability side by side.

Eloralintide (LY3841136) is a selective amylin receptor agonist from Eli Lilly. What the phase 2 trial showed, and how it compares to cagrilintide, petrelintide and amycretin.

Since 1 June 2026 a separate EMA guideline for synthetic peptides applies in the EU. What it covers, who it applies to and why RUO research peptides fall outside it.

The 2026 WADA Prohibited List has applied since 1 January 2026. For research peptides, class S0 is decisive: any pharmacological substance without marketing authorisation is prohibited, and at all times. Semaglutide and tirzepatide are monitored, not prohibited. This article explains the classes, the 2026 changes and the most common misconceptions. Research Use Only.

Diagram of the wound-healing phases (inflammation, proliferation, maturation) and the peptide targets under study — RUOInflammationProliferationMaturationThe phases of wound healing, schematically. Research

Update — 2026: survodutide-onderzoek bij MASH in fase 3 Het survodutide-onderzoek bij MASH heeft in 2026 een grote stap gezet.

Update 2026: AI-ontwerp toegepast op kankervaccins Het duidelijkste toepassingsgebied van AI-peptide-ontwerp in 2026 is het kankervaccin op maat. Een overzichtsartikel

Update 2026: AI en peptiden-kankeronderzoek komen samen In juli 2026 verscheen in Frontiers in Genetics een overzichtsartikel over kunstmatige intelligentie